GPBAR1 and metabolic dysfunction-associated steatotic liver disease: Since both FXR and TGR5 signalling pathways are suppressed in murine models of obesity, it is possible that these derangements contribute to systemic metabolic dysfunction, MASLD progression, and CVD risk.